Selective arterial embolization (SAE) is an established nephron-sparing option for renal angiomyolipoma (AML), but it remains unclear whether giant lesions (≥10 cm) respond less well or carry higher procedural risk. We retrospectively reviewed 40 patients treated with SAE between 2020 and 2025. Tris-acryl gelatin microspheres (300–500 µm) were the primary embolic agent; N-butyl cyanoacrylate or microcoils were added in 12 patients with acute bleeding or large aneurysms. Pre- and post-procedural values were compared with the Wilcoxon signed-rank test, and giant and non-giant lesions with the Mann–Whitney U and Fisher’s exact tests. Thirty-six patients (90%) were women, and 14 (35%) had giant lesions. Technical success reached 100% and clinical success 97.5% (39/40); no major complications occurred. Mean tumor diameter decreased by 13.6% (83.6 ± 47.2 vs. 72.7 ± 41.8 mm; p < 0.001), while estimated glomerular filtration rate (eGFR) did not change significantly (94.6 ± 21.6 vs. 87.7 ± 33.1 mL/min/1.73 m2; p = 0.203). Giant and non-giant lesions did not differ significantly in clinical success (92.9% vs. 100%; p > 0.999), shrinkage, or renal function (all p > 0.05). One patient with a giant, multifocal, tuberous sclerosis complex-associated lesion did not respond and underwent nephrectomy. These data suggest that tumor size alone may not preclude SAE.